Key result
Viabahn stent-grafts show no significant difference in 3-year primary patency compared to Supera stents.
Why the study?
Severe calcification in femoropopliteal disease remains a challenge for endovascular therapy, and this study aimed to compare the long-term safety and efficacy of Viabahn covered stent-grafts and Supera peripheral stents in these lesions.
Does endovascular therapy using Viabahn covered stent-grafts improve 3-year primary patency compared to Supera peripheral interwoven nitinol stents in patients with severely calcified femoropopliteal artery disease?
Cohort (n=341)
Yes
Does endovascular therapy using Viabahn covered stent-grafts improve 3-year primary patency compared to Supera peripheral interwoven nitinol stents in patients with severely calcified femoropopliteal artery disease?
In patients with severely calcified femoropopliteal artery lesions, Viabahn covered stent-grafts and Supera interwoven nitinol stents demonstrated comparable 3-year primary patency, freedom from target lesion revascularization, and limb salvage rates.
Answers are grounded in this paper and cite their sources.
Comparable patency after propensity matching; leaves open optimal stent selection in calcified femoropopliteal lesions pending randomized trials.
Purpose: This study aimed to compare the long-term safety and efficacy of Viabahn covered stent-grafts (CSG) and Supera peripheral stents (SPS) in calcified femoropopliteal artery lesions. Materials and Methods: We retrospectively analyzed 341 cases who had Rutherford class 2 to 6 peripheral artery disease and underwent endovascular therapy (EVT) with either CSG (n = 137) or SPS (n = 204) for femoropopliteal lesions with bilateral calcification assessed by fluoroscopic image based on Peripheral Arterial Calcium Scoring System classification, between April 2017 and February 2021 at 7 cardiovascular centers in our country. Results: Following propensity score (PS) matching, the final study population comprised 142 matched patients with no remarkable intergroup difference in baseline characteristics. The 3-year primary patency was 70.9% in the CSG group and 56.2% in the SPS group, respectively, and was not statistically different ( P = .083). Moreover, no significant difference was noted in freedom from target lesion revascularization (72.8% vs 63.5%, P = .16), limb salvage rate (100.0% vs 96.2%, P = .32), and overall survival rate (67.6% vs 66.6%, P = .61). Stratification analysis revealed that advanced age and current smoking had a significant interaction on the association of CSG versus SPS implantation with restenosis (interaction P < .05). Conclusion: In patients with severely calcified femoropopliteal lesions, the 3-year primary patency was not significantly different between EVT using CSG and SPS following PS matching. Clinical Impact Severe calcification in femoropopliteal disease remains a challenge for EVT. Covered stent-graft and SPS are reliable devices for calcified femoropopliteal lesions. We compared the 3-year outcomes in patients undergoing EVT using either CSG or SPS. Following the propensity matching, the 3-year primary patency was not different at 70.0% and 56.2% ( P = .083) in the CSG (n = 71) and SPS (n = 71) groups, respectively. Moreover, no significant difference was noted in freedom from target lesion revascularization and limb salvage rate.
No takes yet. Share an insight, caveat, or question.
Horie et al. (2026) conducted a cohort in Severely calcified femoropopliteal artery disease (Rutherford class 2 to 6 peripheral artery disease) (n=341). Viabahn covered stent-graft (CSG) vs. Supera peripheral interwoven nitinol stent (SPS) was evaluated on 3-year primary patency (p=0.083). Endovascular therapy using Viabahn covered stent-grafts had a 3-year primary patency not different from Supera peripheral stents after propensity matching.
Synapse has enriched 10 related papers. Consider them for comparative context: